Ikarian Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Ikarian Capital’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-257,700	Closed	-$10.7M	–	193
2025 Q3	$10.7M	Buy	+257,700	New	+$8.24M	1.08%	24
2024 Q2	–	Sell	-8,700	Closed	-$407K	–	127
2024 Q1	$407K	Sell	8,700 -91,300	-91%	-$3.57M	0.04%	124
2023 Q4	$3.56M	Buy	100,000 +95,946	+2,367%	+$2.94M	0.33%	71
2023 Q3	$12.1M	Buy	+4,054	New	+$83.5K	1.45%	18

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Ikarian Capital's CRNX Position: Q4 2025 in Review

Ikarian Capital sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 130,902 shares — an estimated $5.83M sold.

Ikarian Capital first reported a position in CRNX in Q3 2020 and held it in 11 quarters. The position peaked at $30.1M in Q1 2024. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

Ikarian Capital reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Ikarian Capital sold 130,902 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $5.83M.
Ikarian Capital first reported a position in Crinetics Pharmaceuticals in Q3 2020 and held it in 11 quarters.
Ikarian Capital's Crinetics Pharmaceuticals position peaked at $30.1M in Q1 2024.
240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.